194 related articles for article (PubMed ID: 15114009)
1. Construction and isolation of recombinant MVA.
Staib C; Drexler I; Sutter G
Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009
[TBL] [Abstract][Full Text] [Related]
2. Easy and efficient protocols for working with recombinant vaccinia virus MVA.
Kremer M; Volz A; Kreijtz JH; Fux R; Lehmann MH; Sutter G
Methods Mol Biol; 2012; 890():59-92. PubMed ID: 22688761
[TBL] [Abstract][Full Text] [Related]
3. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.
Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG
J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289
[TBL] [Abstract][Full Text] [Related]
4. [Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)].
Ferrer MF; Zanetti FA; Calamante G
Rev Argent Microbiol; 2007; 39(3):138-42. PubMed ID: 17987847
[TBL] [Abstract][Full Text] [Related]
5. High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara.
Hebben M; Brants J; Birck C; Samama JP; Wasylyk B; Spehner D; Pradeau K; Domi A; Moss B; Schultz P; Drillien R
Protein Expr Purif; 2007 Dec; 56(2):269-78. PubMed ID: 17892951
[TBL] [Abstract][Full Text] [Related]
6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
7. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.
Di Lullo G; Soprana E; Panigada M; Palini A; Agresti A; Comunian C; Milani A; Capua I; Erfle V; Siccardi AG
J Virol Methods; 2010 Feb; 163(2):195-204. PubMed ID: 19778556
[TBL] [Abstract][Full Text] [Related]
8. Vectors for recombinational cloning and gene expression in mammalian cells using modified vaccinia virus Ankara.
Pradeau-Aubreton K; Ruff M; Garnier JM; Schultz P; Drillien R
Anal Biochem; 2010 Sep; 404(1):103-5. PubMed ID: 20450873
[TBL] [Abstract][Full Text] [Related]
9. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.
Cottingham MG; Gilbert SC
J Virol Methods; 2010 Sep; 168(1-2):233-6. PubMed ID: 20417665
[TBL] [Abstract][Full Text] [Related]
10. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells.
Nemecková S; Hainz P; Otáhal P; Gabriel P; Sroller V; Kutinová L
Acta Virol; 2001; 45(4):243-7. PubMed ID: 11885931
[TBL] [Abstract][Full Text] [Related]
11. Isolation of recombinant MVA using F13L selection.
Sánchez-Puig JM; Lorenzo MM; Blasco R
Methods Mol Biol; 2012; 890():93-111. PubMed ID: 22688762
[TBL] [Abstract][Full Text] [Related]
12. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
[TBL] [Abstract][Full Text] [Related]
13. Transient host range selection for genetic engineering of modified vaccinia virus Ankara.
Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G
Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279
[TBL] [Abstract][Full Text] [Related]
14. [Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus].
Zheng Q; Li P; Cao R; Hou J; Chen P
Sheng Wu Gong Cheng Xue Bao; 2008 May; 24(5):766-73. PubMed ID: 18724695
[TBL] [Abstract][Full Text] [Related]
15. Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells.
Zwilling J; Sliva K; Schwantes A; Schnierle B; Sutter G
Virology; 2010 Sep; 404(2):231-9. PubMed ID: 20627347
[TBL] [Abstract][Full Text] [Related]
16. [Construction and antigenic evaluation of a recombinant MVA virus-like particle expressing HBV C gene].
Luan XL; Kong W; Liu SJ; Lei L; Hu Y; Hou J; Shen HH; Wu YC; You SL; Mao PY; Xin SJ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):252-4. PubMed ID: 18250055
[TBL] [Abstract][Full Text] [Related]
17. Construction and isolation of recombinant vaccinia virus using genetic markers.
Lorenzo MM; Galindo I; Blasco R
Methods Mol Biol; 2004; 269():15-30. PubMed ID: 15114004
[TBL] [Abstract][Full Text] [Related]
18. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
Volz A; Fux R; Langenmayer MC; Sutter G
Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):464-72. PubMed ID: 26697713
[TBL] [Abstract][Full Text] [Related]
19. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
